Site of Manufacture of Active mRNA Ingredient for Pfizer Covid Vaccine Batches

Catherine Jamieson made this Official Information request to Ministry of Health

Response to this request is long overdue. By law Ministry of Health should have responded by now (details and exceptions). The requester can complain to the Ombudsman.

From: Catherine Jamieson

Dear Ministry of Health,

Prior to 6 October 2021 import of Comirnaty into New Zealand was limited to that where the active mRNA ingredient was manufactured at the following sites:-

1) Wyeth Biopharma, Division of Wyeth Pharmaceuticals LLC
One Burtt Road, Andover Massachussetts 01810 United States of America
2) Rentschler Biopharma SE Erwin-Rentschler-Strasse 21 Laupheim 88471
Germany
3) BioNTech Manufacturing GmbH An der Goldgrube 12
Mainz 5513, Germany

For the following batches of Comirnaty please identify the site of manufacture of the active mRNA ingredient:-

EP2163, EP9605, ER7449, ET3045, FA5833, FC3558, FC5029, FD0927, FD9234, FE2090, FE3064, FE8163, FF2382, FF4206, FF4222, FF8871, FG0050, FG3716, FG7372, FG9019, FH0114, FH3219, FH4091, FH4092

If the site of manufacture of final dose form for any of the above batches differs from

Pfizer Manufacturing Belgium NV Rijksweg 12, Puurs B-2870, Belgium

please identify which batches this applies to and provide identifying name and address of the respective sites.

Yours faithfully,

Catherine Jamieson

Link to this

From: OIA Requests


Attachment image.png
89K Download


Kia ora Catherine,

  

Thank you for your request for official information. The reference number
for your request is: H2024041454

  

As required under the Official Information Act 1982, Manatū Hauora will
endeavour to respond to your request no later than 20 working days after
the day your request was received. If you'd like to calculate the
timeframe, you can use the Ombudsman's online calculator
here: [1]http://www.ombudsman.parliament.nz/  

  

If you have any queries, please feel free to contact the OIA Services Team
on [2][email address]. If any additional factors come to light which
are relevant to your request, please do not hesitate to contact us so that
these can be taken into account.  

Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [3][email address] or by calling 0800
802 602.

Ngā mihi 

 

OIA Services Team 

[4]Ministry of Health information releases 

 

 

------------------- Original Message -------------------
From: Catherine Jamieson
<[FOI #26792 email]>; 
Received: Tue May 14 2024 15:40:11 GMT+1200 (New Zealand Standard Time)
To: OIA Requests <[email address]>; OIA <[email address]>; 
Subject: Official Information request - Site of Manufacture of Active mRNA
Ingredient for Pfizer Covid Vaccine Batches

Dear Ministry of Health,

Prior to 6 October 2021 import of Comirnaty into New Zealand was limited
to that where the active mRNA ingredient was manufactured at the following
sites:-

1) Wyeth Biopharma, Division of Wyeth Pharmaceuticals LLC
One Burtt Road, Andover Massachussetts 01810 United States of America 
2) Rentschler Biopharma SE Erwin-Rentschler-Strasse 21 Laupheim 88471
Germany 
3) BioNTech Manufacturing GmbH An der Goldgrube 12
Mainz 5513, Germany 

For the following batches of Comirnaty please identify the site of
manufacture of the active mRNA ingredient:-

EP2163, EP9605, ER7449, ET3045, FA5833, FC3558, FC5029, FD0927, FD9234,
FE2090, FE3064, FE8163, FF2382, FF4206, FF4222, FF8871, FG0050, FG3716,
FG7372, FG9019, FH0114, FH3219, FH4091, FH4092

If the site of manufacture of final dose form for any of the above batches
differs from 

Pfizer Manufacturing Belgium NV Rijksweg 12, Puurs B-2870, Belgium 

please identify which batches this applies to and provide identifying name
and address of the respective sites.

Yours faithfully,

Catherine Jamieson
 

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

References

Visible links
1. http://www.ombudsman.parliament.nz/
2. mailto:[email address]
3. mailto:[email address]
4. https://www.health.govt.nz/about-ministr...

hide quoted sections

Link to this

From: OIA Requests


Attachment Outlook unni53on.png
80K Download


Tçnâ koe Catherine,
 
Thank you for your request under the Official Information Act 1982 (the
Act) to Manatû Hauora (the Ministry of Health) on 14 May 2024.
 
Manatû Hauora does not hold any information relating to your request;
however, I have been advised that this information is held by Te Whatu Ora
– Health New Zealand. For this reason, I have decided to
transfer your request to their agency under section 14(b)(i) of the Act.
You can expect a response from Te Whatu Ora ([1][email address])
in due course.  
 
Under section 28(3) of the Act, you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [2][email address] or by calling 0800
802 602.

Ngâ mihi 

  

OIA Services Team

Manatû Hauora | Ministry of Health

M[3]inistry of Health information releases 
U[4]nite against COVID-19 

 

------------------- Original Message -------------------
From: Catherine Jamieson
<[FOI #26792 email]>; 
Received: Tue May 14 2024 15:40:11 GMT+1200 (New Zealand Standard Time)
To: OIA Requests <[email address]>; OIA <[email address]>; 
Subject: Official Information request - Site of Manufacture of Active mRNA
Ingredient for Pfizer Covid Vaccine Batches

Dear Ministry of Health,

Prior to 6 October 2021 import of Comirnaty into New Zealand was limited
to that where the active mRNA ingredient was manufactured at the following
sites:-

1) Wyeth Biopharma, Division of Wyeth Pharmaceuticals LLC
One Burtt Road, Andover Massachussetts 01810 United States of America 
2) Rentschler Biopharma SE Erwin-Rentschler-Strasse 21 Laupheim 88471
Germany 
3) BioNTech Manufacturing GmbH An der Goldgrube 12
Mainz 5513, Germany 

For the following batches of Comirnaty please identify the site of
manufacture of the active mRNA ingredient:-

EP2163, EP9605, ER7449, ET3045, FA5833, FC3558, FC5029, FD0927, FD9234,
FE2090, FE3064, FE8163, FF2382, FF4206, FF4222, FF8871, FG0050, FG3716,
FG7372, FG9019, FH0114, FH3219, FH4091, FH4092

If the site of manufacture of final dose form for any of the above batches
differs from 

Pfizer Manufacturing Belgium NV Rijksweg 12, Puurs B-2870, Belgium 

please identify which batches this applies to and provide identifying name
and address of the respective sites.

Yours faithfully,

Catherine Jamieson
 

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

References

Visible links
1. mailto:[email address]
2. mailto:[email address]
3. https://www.health.govt.nz/about-ministr...
4. https://covid19.govt.nz/

hide quoted sections

Link to this

From: hnzOIA

Tēnā koe, 

 

Thank you for contacting Health NZ, Te Whatu Ora. This is an automatic
reply to confirm that we have received your email.  Depending on the
nature of your request you may not receive a response for up to 20 working
days.  We will try to respond to your query as quickly as possible.

 

 

Ngā mihi

 

Health NZ, Te Whatu Ora.

Statement of confidentiality: This email message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege. If you are not the intended recipient, do not read, use,
disseminate, distribute or copy this message or attachments. If you have
received this message in error, please notify the sender immediately and
delete this message

Link to this

From: hnzOIA


Attachment image.png
81K Download

Attachment HNZ00052246 OIA response.pdf
129K Download View as HTML


Kia ora
 
Thank you for your request for information. Please find attached our
response to your request.
 
If you have any questions, please get in touch at
[1][email address].
 
If you are not happy with this response, you have the right to make a
complaint to the Ombudsman. Information about how to do this is available
at [2]www.ombudsman.parliament.nz or by phoning 0800 802 602.
 
Ngā mihi, 
 
Health New Zealand | Te Whatu Ora Ministerial Team 
 
Government Services
Office of the Chief Executive 

Health New Zealand | Te Whatu Ora
Statement of confidentiality: This email message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege. If you are not the intended recipient, do not read, use,
disseminate, distribute or copy this message or attachments. If you have
received this message in error, please notify the sender immediately and
delete this message

References

Visible links
1. mailto:[email address]
2. file:///tmp/

Link to this

From: Catherine Jamieson

Dear hnzOIA,

The question about mRNA active ingredient site of manufacture for each batch has not been addressed in your answer. Given that please do not apply a further 20 day timeframe and provide an answer as soon as possible.

Please in addition please clarify using the phrase 'final dose form' that all batches had final dose form manufactured in Puurs Belgium.

Yours sincerely,

Catherine Jamieson

Link to this

From: hnzOIA

Tēnā koe, 

 

Thank you for contacting Health NZ, Te Whatu Ora. This is an automatic
reply to confirm that we have received your email.  Depending on the
nature of your request you may not receive a response for up to 20 working
days.  We will try to respond to your query as quickly as possible.

 

 

Ngā mihi

 

Health NZ, Te Whatu Ora.

Statement of confidentiality: This email message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege. If you are not the intended recipient, do not read, use,
disseminate, distribute or copy this message or attachments. If you have
received this message in error, please notify the sender immediately and
delete this message

Link to this

From: hnzOIA


Attachment image.png
81K Download


Kia ora Catherine,
 
Thank you for your request of 26 June for the following information:
 
The question about mRNA active ingredient site of manufacture for each
batch has not been addressed in your answer.  Given that please do not
apply a further 20 day timeframe and provide an answer as soon as
possible.
Please in addition please clarify using the phrase 'final dose form' that
all batches had final dose form manufactured in Puurs Belgium.
 
Your request asks for information which is more closely aligned with the
functions of Manatū Hauora | Ministry of Health.  For this reason, Health
New Zealand has decided to transfer your request in full to the Ministry
of Health under section 14(b)(ii) of the Act.  You can expect a response
from the Ministry of Health in due course.
 
Under section 28(3) of the Act you have the right to ask the Ombudsman
to review any decisions made under this request. The Ombudsman may be
contacted by email at: [1][email address] or by calling 0800
802 602. If you have any queries related to this request, please do not
hesitate to get in touch.  
 
Ngā mihi, 
 
 
Government Services
Office of the Chief Executive

Health New Zealand | Te Whatu Ora
Statement of confidentiality: This email message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege. If you are not the intended recipient, do not read, use,
disseminate, distribute or copy this message or attachments. If you have
received this message in error, please notify the sender immediately and
delete this message

References

Visible links
1. mailto:[email address]

Link to this

From: OIA Requests


Attachment image.png
89K Download

Attachment image.png
81K Download


Kia ora Catherine
  
Thank you for your request for official information. The reference number
for your request is: H2024046066
  
As required under the Official Information Act 1982, Manatū Hauora will
endeavour to respond to your request no later than 20 working days after
the day your request was received. If you'd like to calculate the
timeframe, you can use the Ombudsman's online calculator
here: [1]http://www.ombudsman.parliament.nz/  
  
If you have any queries, please feel free to contact the OIA Services Team
on [2][email address]. If any additional factors come to light which
are relevant to your request, please do not hesitate to contact us so that
these can be taken into account. 

Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [3][email address] or by calling 0800
802 602.

Ngā mihi 
 
OIA Services Team 
[4]Ministry of Health information releases 
 
 
From: hnzOIA <[email address]>
Sent: Wednesday, 10 July 2024 1:50 pm
To: Catherine Jamieson <[FOI #26792 email]>
Subject: Transfer of your request for official information ref HNZ00054456
CRM:0304852

Kia ora Catherine,
 
Thank you for your request of 26 June for the following information:
 
The question about mRNA active ingredient site of manufacture for each
batch has not been addressed in your answer.  Given that please do not
apply a further 20 day timeframe and provide an answer as soon as
possible.
Please in addition please clarify using the phrase 'final dose form' that
all batches had final dose form manufactured in Puurs Belgium.
 
Your request asks for information which is more closely aligned with the
functions of Manatū Hauora | Ministry of Health.  For this reason, Health
New Zealand has decided to transfer your request in full to the Ministry
of Health under section 14(b)(ii) of the Act.  You can expect a response
from the Ministry of Health in due course.
 
Under section 28(3) of the Act you have the right to ask the Ombudsman
to review any decisions made under this request. The Ombudsman may be
contacted by email at: [5][email address] or by calling 0800
802 602. If you have any queries related to this request, please do not
hesitate to get in touch.  
 
Ngā mihi, 
 
 
Government Services
Office of the Chief Executive

Health New Zealand | Te Whatu Ora
 

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

References

Visible links
1. http://www.ombudsman.parliament.nz/
2. mailto:[email address]
3. mailto:[email address]
4. https://www.health.govt.nz/about-ministr...
5. mailto:[email address]

hide quoted sections

Link to this

Things to do with this request

Anyone:
Ministry of Health only: